Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
MYGNMyriad(MYGN) Newsfilter·2024-02-01 22:25

收购交易 - Myriad Genetics, Inc.宣布完成了从Intermountain Health处收购Intermountain Precision Genomics (IPG)实验室业务的部分资产[1] 产品发展 - Myriad将继续运营TheraMap: Solid Tumor作为Precise Tumor,并计划推出Precise Liquid,提供便捷的全面基因组分析结果[2][3] 增长战略 - 收购使Myriad能够更有效地扩展和增长其肿瘤分析产品,以补充其遗传性癌症和伴随诊断测试选择[4]